Efficacy of a novel bivalent vaccine containing porcine circovirus type 2d and Mycoplasma hyopneumoniae against a dual PCV2d and Mycoplasma hyopneumoniae challenge

• Published in: Frontiers in veterinary science 2023-07, Vol.10, p.1176091-1176091
• Main Authors: Ham, Sehyeong, Suh, Jeongmin, Oh, Taehwan, Kim, Chonghan, Seo, Byoung-Joo, Chae, Chanhee
• Format: Article
• Language: English
• Subjects: bivalent vaccine; enzootic pneumonia; Mycoplasma hyopneumoniae; porcine circovirus type 2d; porcine respiratory disease complex; Veterinary Science
• ISSN: 2297-1769; 2297-1769
• DOI: 10.3389/fvets.2023.1176091

Information on efficacy of a novel bivalent vaccine containing porcine circovirus type 2d (PCV2d) and . To evaluate bivalent vaccine for efficacy under experimental conditions. Clinically healthy 35 weaned piglets at 18 days of age were used. A 2.0 mL dose of bivalent vaccine was administered intramuscularly to pigs at 21 days of age in accordance with the manufacturer's instructions. The pigs were challenged at 42 days of age either intranasally with PCV2d, or intratracheally with , or with both. Vaccinated-challenged pigs improved the growth performance compared to pigs that were unvaccinated and then, challenged. Vaccinated-challenged pigs elicited a significant amount of protective immunity for PCV2d-specific neutralizing antibodies and interferon-γ secreting cells (IFN-γ-SC) as well as for -specific IFN-γ-SC compared to unvaccinated/challenged pigs. Induction of systemic cellular and humoral immune responses from bivalent vaccination reduced the viral and mycoplasmal loads in the blood and larynx. Vaccination and challenge simultaneously reduced both lung and lymphoid lesion severity when compared to unvaccinated-challenged pigs. The results of this study demonstrated that the evaluated bivalent PCV2d and vaccine was efficacious in protecting pigs from the most predominant PCV2d genotype in the field today, as evaluated with a dual PCV2d and challenge under experimental conditions.